RESEARCH · MOTS-C · LUNG, SEPSIS AND HOST DEFENCE
MOTS-c in Lung Injury, Sepsis and Host Defence Research: Infection Models, Surgical Cohorts and Nrf2
PurixLab’s MOTS-C 10mg is a research vial of the 16-amino-acid mitochondrial-derived peptide MOTS-c. Our earlier articles cover a research overview, rodent obesity and diabetes models, exercise and AMPK signalling, circulating levels in humans and bone and cartilage models. This article covers a fast-growing literature on infection, sepsis and the lung: a proposed direct antibacterial role, endotoxaemia and sepsis models, and a cluster of acute and chronic lung injury studies. Nearly all of it is preclinical. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
A mitochondrial-encoded host defence peptide?
Mitochondria descend from bacteria, and a 2026 eLife paper argues that MOTS-c behaves like a host defence peptide. The authors describe it as amphipathic and cationic, report direct activity against Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA) partly by targeting bacterial membranes, and found that MOTS-c fully neutralised MRSA infectivity in a mouse model of acute peritonitis. In human monocytes, interferon gamma, lipopolysaccharide (LPS) and differentiation signals each induced endogenous MOTS-c, and mouse monocytes differentiated in its presence became macrophages with interferon and antigen-presentation signatures and enhanced bacterial clearance [1].
An earlier study had reported that MOTS-c improved survival and reduced bacterial load in MRSA-challenged mice, lowered TNF-α, IL-6 and IL-1β, raised IL-10 and enhanced the bactericidal capacity of macrophages, with reduced MAPK phosphorylation and increased AhR and STAT3 expression [2]. The two papers propose different emphases, direct membrane activity versus immune modulation, and both mechanisms may contribute.
Endotoxaemia and sepsis models
LPS is the standard tool for modelling the inflammatory phase of sepsis. In LPS-induced septic cardiomyopathy, MOTS-c lowered cardiomyocyte cytokine mRNA and circulating CK-MB and troponin T and reduced apoptosis; blocking AMPK with compound C abolished the benefit [3]. A Theranostics study approached the question from the other side: in endothelial cells exposed to LPS, the DNA repair kinase DNA-PKcs repressed MOTS-c transcription through mitochondrial DNA breaks, and restoring MOTS-c improved endothelial barrier function and myocardial microvascular integrity [4]. In LPS-induced sepsis-associated encephalopathy, MOTS-c given before the challenge increased survival, reduced the murine sepsis score and limited blood-brain barrier leakage [5].
Acute lung injury
The lung is the organ most often studied. In mice given intratracheal LPS, MOTS-c pretreatment reduced pulmonary oedema, neutrophil infiltration and TNF-α, IL-1β and IL-6, and increased IL-10, with higher phosphorylated AMPKα and SIRT1 and lower ERK, JNK, p38, p65 and STAT3 activation [6]. A rat model using the bacterial formyl peptide fMLP linked endothelial barrier damage to FPR2-mediated ferroptosis, and MOTS-c protected barrier function through Nrf2 and MAPK pathways [7].
Ischaemia-reperfusion and cardiac surgery
Several groups studied lung injury after cardiac surgery or transplantation, where small human cohorts sit beside animal work. Circulating MOTS-c was lower in patients who developed acute lung injury after off-pump coronary bypass, and in rats MOTS-c suppressed ferroptosis in a PPARγ-dependent manner [8]. In a prospective study of 107 patients undergoing cardiopulmonary bypass, MOTS-c concentrations were reduced in those with acute lung injury, and in experimental models MOTS-c pretreatment enhanced glycolysis via an AMPK-HIF-1α-PFKFB3 pathway [9]. Remote ischaemic preconditioning raised serum MOTS-c in lung transplant patients and mice, and MOTS-c given to mice reproduced the protection through Nrf2 [10]. A Redox Biology study described MOTS-c moving to the endothelial nucleus with MYH9 and binding antioxidant gene promoters; the rise in serum MOTS-c within 24 h after bypass predicted ARDS with an AUC of 0.885 in multivariate models [11].
Radiation, allergic airway and neonatal hyperoxia models
Beyond acute injury, MOTS-c reduced lung damage, inflammation and oxidative stress in mice exposed to 20 Gy of lung irradiation and treated for 2 weeks, and Nrf2 deficiency abolished the effect [12]. A follow-up engineered an analogue, R13A-MOTS-c, replacing arginine at position 13 with alanine to raise the hydrophobicity index from -0.938 to -0.544; uptake depended on the LAT1 transporter [13]. In a house dust mite asthma model, serum MOTS-c was lower in patients with asthma than in healthy volunteers, and MOTS-c protected the airway epithelial barrier through Nrf2 [14]. In neonatal mice exposed to 70% oxygen, a model of bronchopulmonary dysplasia, MOTS-c attenuated alveolar simplification and abnormal vessel formation, again in an Nrf2-dependent manner [15].
Adaptive immunity
MOTS-c also acts on T cells. In non-obese diabetic mice it reduced islet-infiltrating immune cells through TCR/mTORC1 signalling, as discussed in our obesity and diabetes article [16]. Together with the macrophage data [1,2], this suggests effects on both innate and adaptive immune cells, though the cellular target varies between studies.
Reading this literature critically
- Prevention, not rescue. Most studies gave MOTS-c before or at the time of injury [6,5,9], which is easier to show than reversal of established disease.
- One recurring pathway. Nrf2 dependence appears in many papers [10,12,14,15]. Several of the cardiac-surgery and ferroptosis papers share authors [8,7,9,11], so the number of independent replications is smaller than the paper count suggests.
- Human data are associations. Lower circulating MOTS-c in surgical and asthma cohorts [8,9,14] does not show cause, and assay limits apply (see our circulating-levels article).
- Reviews. A 2026 review positions MOTS-c as a candidate biomarker and therapeutic target in lung disease but calls for well-designed translational and multicentre clinical studies [17].
What remains open
- Whether the direct antibacterial activity matters at physiological concentrations.
- Whether any of the lung findings hold in large animals or in controlled human studies.
MOTS-C 10mg at PurixLab
MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Rice MC, Imun M, Jung SW, et al. MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. Elife. 2026;12:RP87615. PubMed 42611943 · PMC13485304 · doi:10.7554/eLife.87615
- Zhai D, Ye Z, Jiang Y, et al. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol. 2017;92:151-160. PubMed 29096170 · doi:10.1016/j.molimm.2017.10.017
- Wu J, Xiao D, Yu K, et al. The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy. Acta Biochim Biophys Sin (Shanghai). 2023;55(2):285-294. PubMed 36786072 · PMC10157545 · doi:10.3724/abbs.2023006
- Zou R, Shi W, Chang X, et al. The DNA-dependent protein kinase catalytic subunit exacerbates endotoxemia-induced myocardial microvascular injury by disrupting the MOTS-c/JNK pathway and inducing profilin-mediated lamellipodia degradation. Theranostics. 2024;14(4):1561-1582. PubMed 38389837 · PMC10879869 · doi:10.7150/thno.92650
- Bai Y, Wu H, Wang X, et al. A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure. Int J Neurosci. 2026;136(3):329-342. PubMed 40753494 · doi:10.1080/00207454.2025.2542883
- Xinqiang Y, Quan C, Yuanyuan J, et al. Protective effect of MOTS-c on acute lung injury induced by lipopolysaccharide in mice. Int Immunopharmacol. 2020;80:106174. PubMed 31931370 · doi:10.1016/j.intimp.2019.106174
- Wen Z, Fan J, Zhan F, et al. The role of FPR2-mediated ferroptosis in formyl peptide-induced acute lung injury against endothelial barrier damage and protective effect of the mitochondria-derived peptide MOTS-c. Int Immunopharmacol. 2024;131:111911. PubMed 38527401 · doi:10.1016/j.intimp.2024.111911
- Lu P, Li X, Li B, et al. The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. Eur J Pharmacol. 2023;953:175835. PubMed 37290680 · doi:10.1016/j.ejphar.2023.175835
- Shen Z, Lu P, Jin W, et al. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. Am J Respir Cell Mol Biol. 2025;73(3):353-368. PubMed 40035775 · doi:10.1165/rcmb.2024-0533OC
- Wang DD, Xu B, Sun JJ, et al. MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction. Free Radic Biol Med. 2025;229:127-138. PubMed 39827923 · doi:10.1016/j.freeradbiomed.2025.01.016
- Li X, Zhan F, Qiu G, et al. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. Redox Biol. 2025;84:103681. PubMed 40403491 · PMC12150175 · doi:10.1016/j.redox.2025.103681
- Zhang Y, Huang J, Zhang Y, et al. The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. Antioxidants (Basel). 2024;13(5):613. PubMed 38790718 · PMC11117534 · doi:10.3390/antiox13050613
- Zhang YL, Huang G, Li SP, et al. LAT1-mediated delivery of engineered R13A-MOTS-c attenuates radiation-induced lung injury via Nrf2 activation and mitochondrial protection. Redox Biol. 2026;94:104204. PubMed 42142418 · PMC13199819 · doi:10.1016/j.redox.2026.104204
- Zhang W, Li S, Zhang Y, et al. MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via Nrf2 pathway. Int Immunopharmacol. 2025;161:115014. PubMed 40472776 · doi:10.1016/j.intimp.2025.115014
- Chen D, Zhou MH, Zhu WY, et al. Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway. Eur J Pharmacol. 2026;1019:178726. PubMed 41802484 · doi:10.1016/j.ejphar.2026.178726
- Kong BS, Min SH, Lee C, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep. 2021;36(4):109447. PubMed 34320351 · PMC10083145 · doi:10.1016/j.celrep.2021.109447
- Amado CA, Agüero J, García-Unzueta M, et al. MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases. J Transl Med. 2026;24(1):1031. PubMed 42243958 · PMC13466091 · doi:10.1186/s12967-026-08398-2